ARCA biopharma, Inc. Employee Directory
Biotechnology ResearchColorado, United States11-50 Employees
ARCA biopharma is a biotechnology research company pursuing a precision medicine approach to cardiovascular drug development. It aims to tailor treatments to individual genetic profiles to improve efficacy and patient outcomes while potentially reducing healthcare costs. Its lead program, Gencaro (bucindolol hydrochloride), is being developed as a preventive therapy for atrial fibrillation, with genetic variations in cardiac receptors identified to forecast patient response and guide treatment decisions. The company is also developing rNAPc2 as a potential treatment for RNA-associated diseases, with initial focus on COVID-19. Based in Westminster, Colorado, ARCA operates as a small to mid-sized firm in the biotechnology research sector. A notable recent development is the May 2024 announcement of a merger with Orukatx. That merger provides context to its ongoing corporate and research activities.